Replicel Life Sciences Inc REPCF

Primary Symbol: V.RP

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Joke

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Aug 20, 2024 4:31pm

97 Views

Post# 36188673

RE:Joke

Another week ! I don't think it is a stretch to think this takeover deal has come off the rails.

In the meantime the trading halt should be lifted. The first trade halt was March 15th "pending news". March 18th the "news" was released.
The second trading halt was May 8th by the BCSC due to a failure to file the audited annual financial statements. On May 16th the audited annual financial statements were filed.

There is no reason the trading halt cannot be lifted. If Andrew Schutte cannot get this takeover proposal in front of the shareholders in a timely manner it should be blocked by the BCSC and trading should resume.

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?